Publications (original articles or review articles) published in 2021 from OUS - Metastasis Biology and Experimental Therapeutics (Mælandsmo)
20 publications found
Detection of phenotype-specific therapeutic vulnerabilities in breast cells using a CRISPR loss-of-function screen
Mol Oncol, 15 (8), 2026-2045
DOI 10.1002/1878-0261.12951, PubMed 33759347
Low Concordance Between T-Cell Densities in Matched Primary Tumors and Liver Metastases in Microsatellite Stable Colorectal Cancer
Front Oncol, 11, 671629
DOI 10.3389/fonc.2021.671629, PubMed 34178659
RAB5A expression is a predictive biomarker for trastuzumab emtansine in breast cancer
Nat Commun, 12 (1), 6427
DOI 10.1038/s41467-021-26018-z, PubMed 34741021
Reprogrammed transsulfuration promotes basal-like breast tumor progression via realigning cellular cysteine persulfidation
Proc Natl Acad Sci U S A, 118 (45)
DOI 10.1073/pnas.2100050118, PubMed 34737229
Oncolytic peptides DTT-205 and DTT-304 induce complete regression and protective immune response in experimental murine colorectal cancer
Sci Rep, 11 (1), 6731
DOI 10.1038/s41598-021-86239-6, PubMed 33762676
Circulating Tumor Cell Persistence Associates with Long-Term Clinical Outcome to a Therapeutic Cancer Vaccine in Prostate Cancer
J Pers Med, 11 (7)
DOI 10.3390/jpm11070605, PubMed 34206815
Protein Signature Predicts Response to Neoadjuvant Treatment With Chemotherapy and Bevacizumab in HER2-Negative Breast Cancers
JCO Precis Oncol, 5
DOI 10.1200/PO.20.00086, PubMed 34036235
True and Missed Interval Cancer in Organized Mammographic Screening: A Retrospective Review Study of Diagnostic and Prior Screening Mammograms
Acad Radiol, 29 Suppl 1, S180-S191
DOI 10.1016/j.acra.2021.03.022, PubMed 33926794
EMT-Derived Alterations in Glutamine Metabolism Sensitize Mesenchymal Breast Cells to mTOR Inhibition
Mol Cancer Res, 19 (9), 1546-1558
DOI 10.1158/1541-7786.MCR-20-0962, PubMed 34088869
Argininosuccinate lyase is a metabolic vulnerability in breast development and cancer
NPJ Syst Biol Appl, 7 (1), 36
DOI 10.1038/s41540-021-00195-5, PubMed 34535676
Fibroblast Growth Factor 2 Conjugated with Monomethyl Auristatin E Inhibits Tumor Growth in a Mouse Model
Biomacromolecules, 22 (10), 4169-4180
DOI 10.1021/acs.biomac.1c00662, PubMed 34542998
MicroRNA in combination with HER2-targeting drugs reduces breast cancer cell viability in vitro
Sci Rep, 11 (1), 10893
DOI 10.1038/s41598-021-90385-2, PubMed 34035375
Immune checkpoint B7-H3 protein expression is associated with poor outcome and androgen receptor status in prostate cancer
Prostate, 81 (12), 838-848
DOI 10.1002/pros.24180, PubMed 34125445
Karonudib has potent anti-tumor effects in preclinical models of B-cell lymphoma
Sci Rep, 11 (1), 6317
DOI 10.1038/s41598-021-85613-8, PubMed 33737576
Biodistribution of Poly(alkyl cyanoacrylate) Nanoparticles in Mice and Effect on Tumor Infiltration of Macrophages into a Patient-Derived Breast Cancer Xenograft
Nanomaterials (Basel), 11 (5)
DOI 10.3390/nano11051140, PubMed 33924869
Proteomic analyses identify major vault protein as a prognostic biomarker for fatal prostate cancer
Carcinogenesis, 42 (5), 685-693
DOI 10.1093/carcin/bgab015, PubMed 33609362
Novel human melanoma brain metastasis models in athymic nude fox1nu mice: Site-specific metastasis patterns reflecting their clinical origin
Cancer Med, 10 (23), 8604-8613
DOI 10.1002/cam4.4334, PubMed 34612023
Trafficking of Full-Length and N-Terminally Truncated Cathepsin B in Human Colorectal Carcinoma Cells
Appl. Sci.-Basel, 11 (24), 11936
DOI 10.3390/app112411936
Mechanism of cellular uptake and cytotoxicity of paclitaxel loaded lipid nanocapsules in breast cancer cells
Int J Pharm, 597, 120217
DOI 10.1016/j.ijpharm.2021.120217, PubMed 33486035
Benefit-Risk Assessment of Off-Label Drug Use in Children: The Bravo Framework
Clin Pharmacol Ther, 110 (4), 952-965
DOI 10.1002/cpt.2336, PubMed 34145575